ABSTRACT Fifteen patients with congestive cardiomyopathy (six idiopathic and nine alcoholic) manifested by heart failure (New York Heart Association class III or IV) were randomly assigned to a protocol in which dobutamine (n = 8) or 5% dextrose in water (n = 7) was infused continuously for 72 hr. The dose of dobutamine was titrated to increase cardiac output to twice the baseline values. The patients were evaluated before infusion, shortly after infusion, and 1, 2, and 4 weeks thereafter. Functional class improved in six of eight dobutamine-treated patients but in only two of seven control patients during the 4 week observation period. Maximal exercise time and left ventricular ejection fraction increased significantly above baseline only in the dobutamine group. However, neither dobutamine nor placebo infusion produced significant changes shortly after infusion in heart rate, cardiac index, or total peripheral vascular resistance at rest or during exercise at similar workloads. The group receiving dobutamine did show a reduction in systemic systolic and pulmonary arterial mean and diastolic pressure at rest (123 + 5 to 108 + 6, 32 ± 5, to 24 ± 3, and 26 + 4 to 20 ± 2 mm Hg, respectively). In addition, total body oxygen consumption during similar workloads was lower after dobutamine infusion than before. These changes occurred without alteration in plasma catecholamine or arterial blood lactate concentrations. The improvement in resting hemodynamics, exercise tolerance, and symptoms observed for at least several weeks after dobutamine infusion suggests that there is a sustained effect on cardiac function after short-term inotropic stimulation. This may represent an innovative form of long-term therapy for debilitating cardiac failure. Circulation 69, No. 1, 113-119, 1984. DOBUTAMINE, a synthetic sympathomimetic amine with predominant 1,3-adrenergic activity, is a potent inotropic agent that is less arrhythmogenic and chronotropic than naturally occurring catecholamines. 
mechanism for the sustained effects of dobutamine in the failing heart are not known. Limited data have been reported pertaining to parameters of metabolism or function that may be altered by continuous dobutamine infusion in patients with severe congestive heart failure.
The purpose of this double-blind controlled study was to determine whether 72 hr of continuous dobutamine infusion in patients with symptomatic congestive cardiomyopathy is associated with any hemodynamic or metabolic alterations of cardiovascular function to account for the sustained improvement in left ventricular performance.
Methods
Patient selection. Thirteen men and two women (table 1) with either idiopathic or alcoholic cardiomyopathy manifested by stable chronic congestive heart failure (New York Heart Association class III or IV) were randomly assigned to a protocol in which dobutamine (n -8) or 5% dextrose in water (n = 7) was infused continuously for 72 hr. Informed consent was obtained from all patients. None of the patients had severe aortic or mitral stenosis, atrial fibrillation, angina pectoris, acute myo- Simultaneously, arteriovenous oxygen difference (table 4) and total body oxygen consumption (figure 4) increased. Maximum total body oxygen consumption did not differ between the dobutamine (722 ± 97 ml/ min) and placebo (748 ± 112 ml/min) groups before the infusion. However, total body oxygen consumption in the dobutamine group at exercise I was significantly lower in the postinfusion period compared with that in the preinfusion period ( figure 4 ). This improvement was not seen in the placebo group (from 748 ± 112 before to 680 ± 72 ml/min after the infusion).
In the immediate postinfusion exercise test, the resting hemodynamic values were similar to those before infusion, except that the systemic and pulmonary arterial blood pressures were significantly lower and the arteriovenous oxygen difference was significantly smaller than the respective preinfusion values in the dobutamine-treated patients. However, responses of these hemodynamic parameters to exercise were similar to those that occurred before infusion.
Changes in blood lactate levels, lactate-to-pyruvate ratio, and plasma norepinephrine levels are shown in table 4. At rest there was no significant change from the baseline evaluation in any of these parameters after the infusion period in either the dobutamine or the placebo group. Exercise increased blood lactate levels, the lactate-to-pyruvate ratio, and plasma norepineph- resting heart rate. It cannot be concluded from these data, however, whether or not a conditioning effect was produced. Interpretation of the results are further hampered by our lack of information regarding conditioning effects in patients with congestive heart failure. These patients might not respond to physical training with changes that usually occur in healthy individuals.
The reason for the lowered arterial pressure after dobutamine infusion is unclear. Since plasma norepinephrine levels did not change after dobutamine infusion, the decrease in blood pressure probably was not caused by a reduction in sympathetic tone. Nevertheless, it might be caused by the a-receptor blocking property of the ( + )-isomer of dobutamine ' or its metabolites, although this mechanism is entirely hypothetical at this time. The reduction in mean pulmonary arterial and pulmonary arterial diastolic pressure prob-ably was related to the decrease in systemic arterial blood pressure, e.g., decreased afterload, as well as to an improvement in cardiac function.
Thus our present study shows that short-term dobutamine infusion in patients with congestive cardiomyopathies was effective in bringing about improvements in symptoms and exercise tolerance over several weeks. This therapy appears to be a promising modality for the long-term treatment for severe cardiac failure. However, many of these improvements were not observed until long after the infusion of dobutamine was completed. Further studies are warranted to determine how long these improvements will last and whether and to what degree repeated infusions allow persistence of this effect. Studies also are needed to study whether such infusions would alter mortality in patients with congestive heart failure. In addition, the mechanism of the improvement and the factors that account for its time course remain unclear but may be related to reparative processes that dobutamine may effect. Unverferth et al. '8 22 have shown that a 72 hr dobutamine infusion caused an improvement of myocardial mitochondrial structure and increased the ATP/ creatine ratios of the endocardial biopsy specimens in patients similar to ours. The time course for any additional changes remains unknown, but there appears to be an ultrastructural basis for the observations we have made. Additional studies are needed to investigate the mechanism by which these mitochondrial changes occur and their significance.
